Education
About Us
Working with TipRanks
Follow Us
Haemonetics (HAE)
:HAE
HAE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$50.68 - $94.99
Previous CloseN/A
Volume53.78K
Average Volume (3M)1.05M
Market Cap
$2.66B
Enterprise Value$4.50B
Total Cash (Recent Filing)$292.90M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)16.8
Beta0.74
Next Earnings
Nov 05, 2025EPS Estimate
1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.10
Shares Outstanding48,177,258
10 Day Avg. Volume1,136,566
30 Day Avg. Volume1,053,736
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.69
Enterprise Value/Revenue3.34
Enterprise Value/Gross Profit5.96
Enterprise Value/Ebitda12.99
Forecast
1Y Price Target
$73.00Price Target Upside32.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
EarningsNon-GAAP EPS came in at $1.10, exceeding both the internal estimate and the consensus estimate of $1.02.
Financial PerformanceHaemonetics generated $321.4 million in revenue, which exceeded both the internal estimate and the consensus estimate.
Plasma Segment PerformancePlasma revenue came in ahead of expectations by $19M, highlighting strong performance in this segment.
Bears Say
Competitive PressuresIncreased competition for VASCADE has prompted leadership and sales force changes at HAE.
Interventional Technologies ChallengesThe interventional technologies business within the hospital unit declined 7.2% on a reported basis and was down 7.5% organically, rattling investors.
Operational ChallengesThe company is facing operational challenges with numbers continuing to move lower off of execution.
Haemonetics News
HAE FAQ
What was Haemonetics’s price range in the past 12 months?
Haemonetics lowest stock price was $50.68 and its highest was $94.98 in the past 12 months.
What is Haemonetics’s market cap?
Haemonetics’s market cap is $2.66B.
When is Haemonetics’s upcoming earnings report date?
Haemonetics’s upcoming earnings report date is Nov 05, 2025 which is in 68 days.
How were Haemonetics’s earnings last quarter?
Haemonetics released its earnings results on Aug 07, 2025. The company reported $1.1 earnings per share for the quarter, beating the consensus estimate of $1.008 by $0.092.
Is Haemonetics overvalued?
According to Wall Street analysts Haemonetics’s price is currently Undervalued.
Does Haemonetics pay dividends?
Haemonetics does not currently pay dividends.
What is Haemonetics’s EPS estimate?
Haemonetics’s EPS estimate is 1.11.
How many shares outstanding does Haemonetics have?
Haemonetics has 48,177,258 shares outstanding.
What happened to Haemonetics’s price movement after its last earnings report?
Haemonetics reported an EPS of $1.1 in its last earnings report, beating expectations of $1.008. Following the earnings report the stock price went down -26.58%.
Which hedge fund is a major shareholder of Haemonetics?
Currently, no hedge funds are holding shares in HAE
Haemonetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$73.00 (32.65% Upside)
$73.00 (32.65% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 93.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 22.0%
Last 30 Days ▲ 22.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.62%
12-Months-Change
Fundamentals
Return on Equity
18.27%
Trailing 12-Months
Asset Growth
-3.10%
Trailing 12-Months
Company Description
Haemonetics
Haemonetics Corporation (HAE) is a global healthcare company that specializes in blood management solutions. Founded in 1971 and headquartered in Braintree, Massachusetts, Haemonetics operates in various sectors including blood component collection, transfusion medicine, and surgical blood management. Its core products and services include automated blood collection systems, blood processing equipment, and software solutions designed to enhance the efficiency and safety of blood management practices in hospitals and blood centers worldwide.
HAE Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a strong performance in key growth areas, particularly in the plasma and hemostasis management segments, with significant margin expansion and strategic share buybacks contributing to earnings growth. However, challenges remain in the interventional technologies and overall revenue declined due to portfolio transitions. The company is optimistic about overcoming these challenges with strategic initiatives.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$73.00
▲(32.65% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
41.91% Mutual Funds
30.85% Other Institutional Investors
0.49% Public Companies and
Individual Investors